Clinical Trial: Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC

U.S., Jan. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07341100) titled 'Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC' on Dec. 18, 2025.

Brief Summary: This is a multicenter, open-label study to evaluate the preliminary efficacy of SKB264 and the effect of clarithromycin on the PK of SKB264 in patients with ovarian epithelial cancer.

Study Start Date: Jan., 2026

Study Type: INTERVENTIONAL

Condition: Ovarian Epithelial Cancer

Intervention: DRUG: SKB264

4 mg/kg, administered once every 2 weeks (Q2W) by intravenous infusion. It will be administered on Day 1 and Day 17 of Cycle 1, and from Cycle 2 onwards, on Day 1 and Day 15 of each 4...